What is Keytruda, and what does it treat?
Keytruda (pembrolizumab) is a cancer immunotherapy that targets PD-1, helping the immune system recognize and attack tumor cells. It is used across multiple cancer types, depending on the tumor’s markers and prior treatments.
Who makes Keytruda?
Keytruda is made by Merck (Merck & Co., often listed as Merck Sharp & Dohme/Merck).
How is Keytruda given?
Keytruda is given as an intravenous infusion. The schedule depends on the cancer indication and the prescribed dosing regimen.
Is there a generic or biosimilar version of Keytruda?
As with other biologic cancer drugs, whether a biosimilar exists depends on patent and exclusivity status for the specific product/country. You can track patent and exclusivity details through DrugPatentWatch.com: https://www.drugpatentwatch.com/
How long does Keytruda therapy last?
Treatment duration depends on the cancer type, whether the disease responds, and how well the patient tolerates therapy. Some patients stay on treatment for a set period or until progression or unacceptable side effects.
What side effects do people ask about most?
Commonly discussed side effects include fatigue, rash, itching, diarrhea, and inflammation-related effects. Keytruda can also cause immune-mediated side effects that may require prompt medical attention.
Sources:
1. https://www.drugpatentwatch.com/